ELMD Electromed

Electromed, Inc. Launches SmartVest Connect™ Wireless Technology for SmartVest® SQL®

Electromed, Inc. (NYSE MK:ELMD) today announced the late June launch of the SmartVest® SQL® with SmartVest Connect wireless technology, a personalized high frequency chest wall oscillation (HFCWO) therapy management portal for patients with compromised pulmonary function. The SmartVest SQL with wireless technology features built-in cellular connectivity, offering healthcare teams and patients access to treatment information to better collaborate in making patient-centered care decisions. SmartVest Connect is available online at https://connect.smartvest.com to pediatric and cystic fibrosis patients using a wirelessly enabled SmartVest SQL system.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170719006104/en/

SmartVest Connect™ Wireless Technology for SmartVest® SQL® (Photo: Business Wire)

SmartVest Connect™ Wireless Technology for SmartVest® SQL® (Photo: Business Wire)

  • SmartVest Connect enables patients to track progress of their therapy plan and includes a real-time SmartVest Score and easy-to-read goal reports that provide an in-depth look at performance.
  • Created to encourage patient engagement, SmartVest Connect provides feedback for patients to take an active role in their HFCWO therapy, fostering improved therapy adherence.
  • SmartVest SQL with SmartVest Connect is simple, intuitive, and designed to automatically update following completion of a therapy session: just plug it in.

“SmartVest Connect is designed to make it easy for healthcare teams and patients to track therapy performance and collaborate in treatment decisions,” commented Kathleen Skarvan, President and Chief Executive Officer of Electromed. “We believe this innovation will strengthen our patient and clinician partnerships, leading to greater therapy adherence and improved quality of life for individuals with compromised pulmonary function. We’re proud to stand by our commitment to ‘making life’s important moments possible’ and continued innovation of delivering market-driven HFCWO therapy solutions. We expect to expand SmartVest Connect availability to targeted adult pulmonary clinics throughout the year.”

The SmartVest System uses HFCWO, a proven therapy that helps clear the lungs of excess secretions, reducing the risk of respiratory infections and hospitalizations. HFCWO produces an alternating flow of air into a garment that rapidly compresses and releases the chest wall at a variety of selectable frequencies and pressures, resulting in an oscillation in airflow within the airways that act to loosen, thin, and propel mucus toward the major airways where it can be expectorated or suctioned away.

About Electromed, Inc.

Electromed manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota and founded in 1992. Further information about the Company can be found at www.smartvest.com.

EN
19/07/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Electromed

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Electromed, Inc. Schedules its Second Quarter Fiscal 2022 Financial Re...

NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2022 second quarter ended December 31, 2021, on Tuesday, February 8, 2022 after the close of the stock market, and host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: (877) 407-0789 (Domestic) (201) 689-8562 (International) The live conference call we...

 PRESS RELEASE

Electromed, Inc. to Participate in the Sidoti December Virtual Micro C...

NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that Kathleen Skarvan, President and Chief Executive Officer, and Mike MacCourt, Chief Financial Officer, are scheduled to participate in the Sidoti December Virtual Micro Cap Investor Conference on December 8-9, 2021. Management will be available for one-on-ones throughout both days. Below are the details for Electromed’s group presentation: Sidoti December Virtual Micro Cap Investor Conference Date: Wednesday, Dece...

 PRESS RELEASE

Electromed, Inc. Announces Fiscal 2022 First Quarter Financial Results

NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended September 30, 2021 (“Q1 FY 2022”). Q1 FY 2022 Highlights Net revenue increased 25.0% to $10.0 million, from $8.0 million for the three months ended September 30, 2020 (“Q1 FY 2021”), driven by 24.4% home care revenue growth and 61.5% institutional revenue growth. Gross profit percentage increased to 77.0% of net revenue, from 76.8% of net revenue in Q1 FY 2021. The inc...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch